|
Market Closed -
Other stock markets
|
After hours 03:37:37 pm | |||
| 70.20 EUR | -0.92% |
|
69.95 | -0.36% |
Business description: bioMérieux
- medical applications (84.3%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.7%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East /Africa (32.3%), North America (45.4%), Asia/Pacific (15.6%), and Latin America (6.7%).
Number of employees: 14,894
Sales by Activity: bioMérieux
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Clinical Applications | 2.88B | 3.04B | 3.1B | 3.37B | 3.43B |
Industrial Applications | 492M | 549M | 575M | 606M | 639M |
Geographical breakdown of sales: bioMérieux
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
United States | - | - | - | - | 1.78B |
Europe, The Middle East and Africa (EMEA) Excluding France | 902M | 901M | - | 1.03B | 1.08B |
Asia-Pacific (ASPAC) | 580M | 624M | 638M | 656M | 635M |
Americas (Excl. United States) | - | - | - | - | 341M |
France | 222M | 220M | - | 240M | 236M |
Corporate | 3.3M | 2.6M | 900K | 600K | 1M |
Americas | 1.67B | 1.84B | 1.85B | 2.05B | - |
Europe, The Middle East and Africa (EMEA) | - | - | 1.19B | - | - |
Executive Committee: bioMérieux
| Manager | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 54 | 2023-06-30 |
| Director of Finance/CFO | 50 | 2018-02-28 | |
| Chief Tech/Sci/R&D Officer | - | 2022-07-31 | |
Charles Cooper
CTO | Chief Tech/Sci/R&D Officer | - | 2024-01-01 |
Jennifer Zinn
CTO | Chief Tech/Sci/R&D Officer | - | 2023-07-31 |
Composition of the Board of Directors: bioMérieux
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 52 | 2017-12-14 | |
| Director/Board Member | 66 | 2004-12-31 | |
| Director/Board Member | 61 | 2012-05-29 | |
| Director/Board Member | 61 | 2012-05-29 | |
Fanny Letier
BRD | Director/Board Member | 47 | 2017-06-29 |
| Director/Board Member | 71 | 2017-08-27 | |
Viviane Monges
BRD | Director/Board Member | 62 | 2024-05-22 |
François Lacoste
BRD | Director/Board Member | 65 | 2026-05-27 |
Holdings: bioMérieux
| Name | Stocks | % | Valuation |
|---|---|---|---|
| 59,062,832 | 6.07% | 97 M $ | |
BIOMÉRIEUX 0.36% | 428,973 | 0.36% | 34 M $ |
Company details: bioMérieux
Group companies: bioMérieux
| Name | Category and Sector |
|---|---|
bioMérieux CZ sro
 bioMérieux CZ sro Medical SpecialtiesHealth Technology Manufactures laboratory equipment |
Medical Specialties
|
bioMérieux China Ltd. (HongKong)
 bioMérieux China Ltd. (HongKong) Medical DistributorsDistribution Services Wholesales and distributes surgical and medical instruments |
Medical Distributors
|
bioMérieux Asia Pacific Pte Ltd. | |
bioMérieux, Inc.
 bioMérieux, Inc. Medical SpecialtiesHealth Technology Develops in-vitro diagnostics solutions |
Medical Specialties
|
bioMérieux Sweden AB |
Diagnostic & Testing Substances
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.92% | -0.50% | -41.30% | -25.27% | 9.53B | |
| +1.23% | -1.77% | +221.54% | +317.61% | 21B | |
| -3.39% | -1.76% | +22.30% | +18.00% | 6.86B | |
| +7.37% | +19.05% | +261.15% | -22.49% | 5.3B | |
| -1.52% | +6.30% | -21.09% | -30.87% | 5.12B | |
| -0.59% | -3.01% | -38.87% | - | 4.82B | |
| +0.29% | +4.00% | -23.02% | -25.71% | 4.2B | |
| +10.01% | -3.79% | +66.21% | +75.55% | 3.42B | |
| +2.15% | +2.38% | -15.80% | -42.94% | 2.63B | |
| +4.66% | -7.36% | -33.12% | +201.79% | 1.55B | |
| Average | +1.88% | +1.54% | +39.80% | +51.74% | 6.44B | |
| Weighted average by Cap. | +1.03% | -0.63% | +85.95% | +111.15% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIM Stock
- Company bioMérieux
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
